The challenges and opportunities of an international approach to benefit-risk

This post is sponsored by DIA.

In 2007, four regulatory authorities from Australia, Canada, Switzerland, and Singapore formed a consortium and identified that there was a need for them to agree on an aligned approach for benefit-risk assessment. The opportunities and challenges of developing such a strategy will be addressed at the DIA 2014 50^th Annual Meeting.

This year’s Annual Meeting, in San Diego from June 15 to 19, will feature a session titled “An International Approach to Benefit-Risk Assessment of Medicines: An Evaluation by a Consortium of Established Agencies” under the Global Regulatory track.

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

The session, to be held on June 18 from 10:30 AM-12:00 PM, will focus on the Heads of Agencies Consortium, which consists of the Therapeutic Goods Administration (TGA) of Australia, Health Canada, and the Health Science Authority (HSA) of Singapore.

The session at the DIA 2014 50^th Annual Meeting will discuss the consortium’s need for a common framework and approach to the review of medicines and address the challenges and opportunities for developing a systematic structured approach to benefit-risk assessment. It will also reveal the outcome of the consortium’s studies. Dr. John Skerritt, National Manager, Therapeutic Goods Administration, Barbara Sabourin, Director-General of Health Canada, and Dr. Raymond Chua, Group Director of Health Sciences Authority of Singapore, will give their views. Professor Stuart Walker, Founder of the Centre for Innovation in Regulatory Science (CIRS) in the United Kingdom, will chair the session.

The DIA 2014 50th Annual Meeting: Celebrate the Past – Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

This year’s event celebrates DIA’s 50^th Anniversary and will feature 260+ educational offerings over 21 tracks, 450+ exhibiting companies, more than 125 representatives from global regulatory agencies, and much more. The meeting provides participants with a valuable opportunity to network with professionals from around the world, share knowledge and build new relationships.